[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-434305-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-434305-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","conditional-relative-survival-an-essential-tool-for-risk-stratification-of-breast-cancer-patients-to-the-editor","Conditional relative survival: an essential tool for risk stratification of (breast) cancer patients - To the editor","","A letter to the editor discusses updated five-year conditional relative survival (5-year CRS) for young breast cancer patients and its value for risk stratification. The letter explains how five-year CRS supports defining time to cure (TTC) and informs policy debates linked to the right to be forgotten, contrasting concerns about insurer risk models with evidence from Netherlands and Italy. It argues that cure-related disclosure and clinical personalization should rely on prognostic risk stratification while avoiding discriminatory effects on survivors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/conditional-relative-survival-an-essential-tool-for-risk-stratification-of-breast-cancer-patients-to-the-editor/434305/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/conditional-relative-survival-an-essential-tool-for-risk-stratification-of-breast-cancer-patients-to-the-editor/434305.png","ImageObject",300,407,{"name":42,"@type":43},"Sophia Brooks","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the role of five-year conditional relative survival (5-year CRS) in the letter?","Question",{"text":63,"@type":64},"It is described as an important “cancer cure” indicator used to define time to cure (TTC) after diagnosis. The letter emphasizes its relevance for risk stratification and survival estimation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the letter connect survival estimates with the “right to be forgotten”?",{"text":68,"@type":64},"It argues that legislation and reference tables may shorten disclosure periods for insurers, but that prognostic-factor stratification is used to further protect survivors from financial toxicity. It also notes resistance from insurers and challenges that position with presented results.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence does the letter cite regarding TTC for young breast cancer patients?",{"text":72,"@type":64},"It reports that young breast cancer survivors in the Netherlands reach TTC after about 7 years overall, with differences by age and stage, and mentions similar consistency with model-based or other-country estimates. For Italy, it highlights high cure prevalence and early TTC for stages I–II in the given cohort.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},434305,1790744180,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":97,"preview_page_count":4},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Journal of the National Cancer Center 5 (2025) 551–552  \nContents lists available at ScienceDirect  \nJournal of the National Cancer Center  \njournal [homepage:](homepage: www.elsevier.com/locate/jncc)[ www.elsevier.com/locate/jncc](homepage: www.elsevier.com/locate/jncc)  \nLetter  \nConditional relative survival: an essential tool for risk stratification of (breast) cancer patients  \nTo the editor,  \nThe article by Vrancken Peeters and colleagues,1 showing updated five-year conditional relative survival (5-year CRS) for young breast cancer patients by relevant prognostic factors and longer follow-up than previous European studies,2 , 3 has filled an important gap in knowledge for the most common cancer among young women.  \nFive-year CRS is an important “cancer cure” indicator, used for defining the time to cure (TTC) after cancer diagnosis, and estimates have been provided extensively for Europe,4 , 5 and European countries6 , 7 based on population-based cancer registries data with or without prognostic factors stratification.  \nTTC constitutes the basis for defining the right to be forgotten8 and, since 2016, several European countries have enacted legislative changes to reduce discrimination against cancer survivors. Adopted laws generally allow any cancer survivor not to declare the previous disease 10 years after the end of active treatment (or in remission) and 5 years if he or she had cancer under age 18. Each country has adopted a “reference table” that allows, for certain types and stages of cancer patients, a shorter period after which insurers must apply standard conditions (e.g., no additional premium). This has to be acknowledged since stratification for prognostic factors is used to shorten the required disclosure period and therefore to protect cancer survivors, young cancer survivors in particular, from financial toxicity. Conversely, requests for more details on prognostic factors and more up-to-date survival estimates are tobe criticised when used by financial institutions and insurers against the right to be forgotten, even limiting its extension in the European Union.  \nThe right to be forgotten has often met with resistance from financial institutions and insurers, who argue that it could undermine their risk assessment and pricing models. The Vrancken Peeters and colleagues’results challenge this position. They showed that young breast cancer survivors in the Netherlands reached the TTC 7 years after diagnosis, 8 years for women aged 30 to 39 (89 % of young breast cancer survivors), from diagnosis for those with stage I at diagnosis, and 6 years for those with stage II (stage I and II represent 77% of breast cancer survivors), and 6 years for young women with HER2+. These results are consistent with those based on model-based estimation of TTC or estimated in other countries. For Italian young breast cancer survivors diagnosed in 2010,7 the TTC is reached by patients as early as diagnosis (end of treatment) for both stage I and II, similar to 5-year CRS at diagnosis of 99.0 % for cases diagnosed at stage I and 94.1 % at stage II in the Netherlands.1 In addition, 81.9 % of Italian young women breast cancer survivors have the same life expectancy as the general population (Table 1),7 , 9 97.3 % when the breast cancer was diagnosed at stage I or 88.1 % at stage II.  \nThese findings should raise questions about the expediency of not applying the right to be forgotten under the justification of a lack of information on prognostic factors. In other words, in clinical decision-making, it is appropriate to personalise decisions on treatment and monitoring through risk stratification in order to adequately meet the specific needs  \nTable 1  \nPrevalence and patients who have the same life expectancy as their peers in the general population (cure prevalence), and TTCa for breast cancer patients aged \u003C 45 years by stage and years since diagnosis in Italy.b  \n\n| Stages | Prevalence in 2018, No. | Cure prevalence |  |  |  | TTC,a , b ","cbCaiaCbPgcib0kP","https://ap.wps.com/l/cbCaiaCbPgcib0kP","pdf",296795,"English","# Letter\n## Conditional relative survival and TTC\n## Legal context: right to be forgotten\n## Evidence from Netherlands and Italy\n## Implications for clinical decisions and public health","[{\"question\":\"What is the role of five-year conditional relative survival (5-year CRS) in the letter?\",\"answer\":\"It is described as an important “cancer cure” indicator used to define time to cure (TTC) after diagnosis. The letter emphasizes its relevance for risk stratification and survival estimation.\"},{\"question\":\"How does the letter connect survival estimates with the “right to be forgotten”?\",\"answer\":\"It argues that legislation and reference tables may shorten disclosure periods for insurers, but that prognostic-factor stratification is used to further protect survivors from financial toxicity. It also notes resistance from insurers and challenges that position with presented results.\"},{\"question\":\"What evidence does the letter cite regarding TTC for young breast cancer patients?\",\"answer\":\"It reports that young breast cancer survivors in the Netherlands reach TTC after about 7 years overall, with differences by age and stage, and mentions similar consistency with model-based or other-country estimates. For Italy, it highlights high cure prevalence and early TTC for stages I–II in the given cohort.\"}]","Conditional relative survival: an essential tool for risk stratification of (breast) cancer patients - To the editor | PDF",1790668471]